Name	Current Price - Today's Change	Market Cap
TECHNE CORP (TECH)	$61.28 - $0.09(0.15%)	2.29 B
BIOVAIL CORP (BVF)	$13.95 - $0.21(1.53%)	2.21 B
MYRIAD GENETICS INC (MYGN)	$21.51 - $0.16(0.74%)	2.13 B
OSI PHARMACEUTICALS INC (OSIP)	$34.45 - $0.28(0.82%)	2.02 B
REGENERON PHARM INC (REGN)	$26.28 - $0.50(1.96%)	2.01 B
ONYX PHARMACEUTICALS INC (ONXX)	$29.32 - $0.86(3.02%)	1.81 B
CHATTEM INC (CHTT)	$93.50 - $0.18(0.19%)	1.77 B
ABRAXIS BIOSCIENCE NEW (ABII)	$38.15 - $0.25(0.65%)	1.57 B
AUXILIUM PHARMACEUTICALS (AUXL)	$30.90 - $0.07(0.23%)	1.46 B
SALIX PHARMACEUTICALS (SLXP)	$27.25 - $0.15(0.55%)	1.35 B

STOCK ANALYSIS

Dendreon Hits The Big Time (DNDN)
Despite positive Phase 3 results, this medicine-maker's valuation is excessive and its new drug won't make it to ma...

Five Companies That Love (Earnings) Surprises (BMRN)
Stocks that can string together many quarters of positive earnings surprises are usually rewarded. Learn why the ma...

View All Stock Analysis

BMRN RELATED HEADLINES

BioMarin Pharmaceutical (BMRN) NewsBite - BMRN Downgraded By Brean Murray
BioMarin Pharmaceutical (BMRN) was downgraded today by analysts at Brean Murray and the stock is now at $18.83, down $0.66 (-3.39%) on volume of 649,064 shares traded. The analysts reduced BMRN to Hold from Buy. Over the last 52 weeks the stock has ranged from a low of $9.93 to a high of $21.50. BioMarin Pharmaceutical stock has...
At Market Intelligence Center 2/8/2010

Pessimism blankets this pharmaceutical concern despite strong price action
BioMarin Pharmaceutical Inc. (BMRN: sentiment, chart, options) has developed three FDA-approved drugs, according to Hoover's, that qualify for orphan drug status, a financial incentive that encourages companies to create drugs for rare diseases by giving the compounds a period of market exclusivity...(Read More)
By SchaeffersResearch 1/20/2010

BioMarin Pharmaceutical (BMRN) NewsBite - BMRN Downgraded By Morgan Joseph
BioMarin Pharmaceutical (BMRN) was downgraded today by analysts at Morgan Joseph and the stock is now at $20.05, down $0.21 (-1.04%) on volume of 1,052,926 shares traded. The analysts downgraded the stock to Hold from Buy. Over the last 52 weeks the stock has ranged from a low of $9.93 to a high of $21.23. BioMarin Pharmaceutical stock has been showing support around $...
At Market Intelligence Center 1/8/2010

BioMarin Pharmaceutical (BMRN) NewsBite - BMRN Upgraded By Collins Stewart
BioMarin Pharmaceutical (BMRN) was upgraded today by analysts at Collins Stewart and the stock is now at $16.81, up $0.19 (1.14%) on volume of 289,415 shares traded. The brokerage upped BMRN to Buy from Hold. Over the last 52 weeks the stock has ranged from a low of $9.93 to a high of $21.23. BioMarin Pharmaceutical stock has been showing support around $16.33...
At Market Intelligence Center 12/9/2009

BioMarin Pharmaceutical (NasdaqNM: BMRN) NewsBite
BioMarin Pharmaceutical (NasdaqNM: BMRN) opened at $17.87. So far today, the stock has hit a low of $16.38 and a high of $17.88. BMRN is now trading at $16.47, up $.79 (5.04%). Over the last 52 weeks the stock has ranged from a low of $9.93 to a high of $21.23. Shares of BMRN are trading higher today after the company reported a third-quarter profit last night of $6.6 million, or 6 cents per share, topping analysts' e...
At Market Intelligence Center 10/29/2009

BioMarin Pharmaceutical (BMRN) NewsBite - BMRN Downgraded By Roth Capital
BioMarin Pharmaceutical (BMRN) was downgraded today by analysts at Roth Capital and the stock is now at $17.13, down $0.73 (-4.09%) on volume of 1,355,298 shares traded. The brokerage downgraded the stock to Hold from Buy. Over the last 52 weeks the stock has ranged from a low of $9.93 to a high of $21.23. BioMarin Pharmaceutical stock has been showing support around ...
At Market Intelligence Center 10/19/2009

View All Headlines